Among them, METTL1 had high-level amplifications above 5% in five TCGA tumor types: lung adenocarcinoma (LUAD, 5.29%), glioblastoma (GBM, 13.57%), sarcoma (SARC, 17.00%), adrenocortical carcinoma (ACC, 6.74%), and cholangiocarcinoma (CHOL, 5.56%). This evidence concerns the gene METTL1 and adrenal cortex carcinoma.